The US generics market has shown a solid growth during the past few years backed by factors, such as government support, increasing awareness level, patent expiry of blockbuster drugs, price differences, and aging population. The generic drugs industry in the US stood at US$ 74 Billion in 2009, and is likely to grow further at a CAGR of around 10% during 2010-2013. In value terms, generic drugs had a share of around 25% in the total US pharmaceutical market during 2009, which is expected to reach around 28% by 2013. All this and various other analyses have been covered in our latest report entitled “Booming US Generic Drug Market”.
Our research report has found that, Proton Pump Inhibitors (PPIs) are witnessing a shift in the number of dispensed prescriptions to generic equivalents and OTC medications. The share of generics in total sales of proton pump inhibitors reached around 50% in 2009 from 45% in 2008, which was a notable trend. Nexium, the fifth-best-selling drug in the world, will go off patent in 2014, and Aciphex does the same in 2013, foretelling even more availability for generic PPis.
The report “Booming US Generic Drug Market”, effectively illustrates the potential for generic drugs sector in key therapy segments, such as Lipid regulators, Antipsychotics, Angiotensin II receptor, Human insulin, Proton pump inhibitors etc. The report also provides an important coverage on the regulatory structure with respect to generics drugs in the US. In this regard, the report illustrates some of the key acts and their important aspects.
The report is an outcome of an in-depth research and prudent analysis of the US generics drugs market that takes into account the factors affecting the market potential. The report also investigates the current market trends and effectively analyzes their impact on the market performance. Forecasting section in the report makes use of proper methods and techniques to show a realistic outlook. Overall, the report is likely to strengthen the knowledge portfolio of clients and investors.
For more information visit: http://www.rncos.com/Report/IM589.htm |
